Nasal Airway Stent (Nastent®) Study in OSA
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Device: Nastent® (a distally perforated soft silicon nasal tube)Diagnostic Test: Polygraphy with WatchPAT™ 300
- Registration Number
- NCT04305964
- Lead Sponsor
- University Hospital, Antwerp
- Brief Summary
This study intends to assess the effect of nasal airway stent (Nasten®) as a treatment modality in patients with sleep-disordered breathing (SDB) including snoring and/or obstructive sleep apnea (OSA). Nastent®, a distally perforated soft silicon nasal tube, is a mechanical splint against collapse of the upper airway at multiple levels. Nastent® might be able to prevent the vibrations caused by fluttering of various parts of the upper airway which leads to snoring. Furthermore, it also potentially secures a patent airway throughout the night securing airflow.
- Detailed Description
Patients with an established diagnosis of OSA with apnea/hypopnea-index (AHI)\< 20/ hour sleep from the ENT department are recruited and informed about the study. After obtaining informed consent and patient inclusion, a baseline portable sleep monitoring at home using WatchPAT™300 for one night is performed. During the next visit the objective size and position of the stent is determined under direct visualization using fiberoptic nasolaryngoscopy. Subsequently, the patients will receive a Nastent® Starter kit (containing 6 different stent sizes of Nastent®, 130, 135, 140, 145, 150 and 155mm) to gradually get accustomed to the stent and to find the right size for them. During the following consultation, a Nastent® classic kit (containing 7 stents of the same size, each can be used for two consecutive nights) is given to the patients to be used for 14 consecutive nights. During the last night of this 14-night period, a follow-up home portable sleep monitoring evaluation using WatchPAT™300 is performed with Nastent® in situ. Afterwards, during the final visit at the outpatient clinic, acceptance of the therapy with Nastent® by the patients is evaluated, and the decision of whether to continue the therapy and to proceed to the purchase of this product as a long-term treatment for the patient or not, is made.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 4
- Age ≥ 18
- AHI ≤ 20 per hour of sleep
- Complaints of socially disturbing snoring by the partner of the patient
- Capable of giving informed consent
- Craniofacial deformities
- Acute nasal trauma, fracture (during the past 3 months)
- Nasal valve collapse, synechiae and septal perforation, recurrent epistaxis, recent nasopharyngeal surgery, chronic rhinosinusitis with or without polyposis
- Cerebrospinal fluid leaks
- History of past or current psychiatric disorders (psychotic illness, major depression, or acute anxiety attacks as mentioned by the patient), intellectual disability, memory disorders, seizure disorders, neuromuscular disorders, cardiovascular diseases, coagulopathies (thrombocytopenia< 100/µl), lower respiratory tract disorders.
- Pregnancy or willing to become pregnant
- Excessive alcohol or drug use (> 20 alcohol units/week or any use of hard drugs)
- History of sleep medication use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Nastent® users Nastent® (a distally perforated soft silicon nasal tube) Patients with an established diagnosis of obstructive sleep apnea with apnea/hypopnea-index (AHI) \< 20/ hour sleep who receive Nastent® as treatment modality Nastent® users Polygraphy with WatchPAT™ 300 Patients with an established diagnosis of obstructive sleep apnea with apnea/hypopnea-index (AHI) \< 20/ hour sleep who receive Nastent® as treatment modality
- Primary Outcome Measures
Name Time Method AHI (apnea-hypopnea index) at follow up after completion of treatment period (an average of three weeks) Number of apneas and hypopneas per hour of sleep which is an indicator of severity of sleep apnea, (5\< normal, 5-15 Mild, 15-30 moderate, \<30 severe)
- Secondary Outcome Measures
Name Time Method Epworth sleepiness scale score (ESS) at follow up after completion of treatment period (an average of three weeks) an 8-item questionnaire which takes about three minutes to fill out. It reflects the chance of each person's general level of sleepiness during eight situations of daily life. The subject selects the most appropriate integer score ranging from 0 (would never doze) to 3 (high chance of dozing) for each of the 8 questions. The results are then summed up, with 0 being the minimal and 24 the maximum total ESS score. The higher the ESS score, the higher that person's average sleep propensity in daily life. (0-5=Lower Normal Daytime Sleepiness, 6-10 = Higher Normal Daytime Sleepiness, 11-12 = Mild Excessive Daytime Sleepiness, 13-15 = Moderate Excessive Daytime Sleepiness, 16-24 =Severe Excessive Daytime Sleepiness.)
VAS (visual analogue scale) for snoring at follow up after completion of treatment period (an average of three weeks) A standard 10-point VAS ranging from 0 (no snoring) to 10 (extreme snoring causing the bed partner to leave the bedroom or sleep separately) will be used to evaluate the subjective status of snoring during sleep. Heavy snoring corresponds to a snoring index of at least 7. A decrease of 3 points after treatment is considered significant. A satisfactory improvements is defined as a reduction to an index that is no longer experiences as bothersome (i.e. \<3).
ODI (oxygen desaturation index) at follow up after completion of treatment period (an average of three weeks) The ODI represents the average number of desaturation episodes (≥3%) per hour sleep.
PAT (peripheral arterial tone) signal at follow up after completion of treatment period (an average of three weeks) PAT™ technology is a non-invasive window to the cardiovascular system and autonomic nervous system. Peripheral Arterial Tone (PAT™) signal is a proprietary technology used for non-invasively measuring arterial tone changes in peripheral arterial beds.
Heart rate at follow up after completion of treatment period (an average of three weeks) The number of times a person's heart beats per minute. Normal heart rate range for adults is 60 to 100 beats per minute.
Body position at follow up after completion of treatment period (an average of three weeks) Percentage of supine, prone, left, right, upright position
Snoring at follow up after completion of treatment period (an average of three weeks) Snoring loudness in decibels
Oxygen saturation (SaO2) at follow up after completion of treatment period (an average of three weeks) A measurement of the percentage of how much hemoglobin is saturated with oxygen
RDI (Respiratory disturbance index) at follow up after completion of treatment period (an average of three weeks) Number of apneas, hypopneas and respiratory-effort related arousals (RERAs) per hour of sleep which is an indicator of severity of sleep apnea
Sleep/wake state at follow up after completion of treatment period (an average of three weeks) Percentage of sleep and wake state
REM sleep at follow up after completion of treatment period (an average of three weeks) Percentage of REM sleep
Deep sleep at follow up after completion of treatment period (an average of three weeks) Percentage of deep sleep
Light sleep at follow up after completion of treatment period (an average of three weeks) Percentage of light sleep
Sleep latency at follow up after completion of treatment period (an average of three weeks) Latency of start of sleep in minutes
REM latency at follow up after completion of treatment period (an average of three weeks) Latency of start of REM sleep in minutes
Total sleep time at follow up after completion of treatment period (an average of three weeks) Total sleep time in minutes
Trial Locations
- Locations (1)
Antwerp University Hospital
🇧🇪Edegem, Antwerp, Belgium